Evolving Paradigms in the Treatment of Philadelphia Chromosome–Positive ALL
American Society of Clinical Oncology Educational Book · 2026-06 · 46 (3)
DOI: 10.1200/edbk-26-517464 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026-06. Verfasst von Nicholas J Short und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer, Houston, TX. Hauptthemen laut MEDLINE: Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 89 Literaturangaben.
Abstract (Originalsprache)
The treatment of adults with Philadelphia chromosome–positive ALL (Ph+ ALL) has evolved significantly over the past 25 years. These changes have been driven largely by the development of potent BCR::ABL1 tyrosine kinase inhibitors (TKIs) such as ponatinib, more accurate risk stratification and monitoring of measurable residual disease (MRD) and, most recently, the frontline use of blinatumomab-based, chemotherapy-free regimens. Although the historical standard of care for newly diagnosed Ph+ ALL was intensive chemotherapy followed by allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in first remission, now most patients can achieve deep and durable remissions—and even cure—with a chemotherapy-free regimen, without the routine need for allo-HSCT. Although the role of allo-HSCT in first remission is diminishing in this new treatment landscape, allo-HSCT remains a reasonable consolidative option for patients with high-risk clinical or molecular features or in treatment settings where frontline blinatumomab and/or high-sensitivity MRD monitoring are not routinely available. With optimal frontline therapy and close disease monitoring, relapses of Ph+ ALL are increasingly uncommon but still pose a significant clinical challenge. Several new agents, including novel TKIs, bispecific antibodies, and chimeric antigen receptor T-cell therapies, are being evaluated in the relapsed/refractory setting and may eventually also play a role in frontline treatment of this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer, Houston, TX.
- Institut d'Investigació Contra La Leucemia Josep Carreras (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
- Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
- Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Centre de Recherche Saint-Antoine INSERM UMRs 938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Sorbonne Université, Paris, France.
- Department of Clinical Haematology, Institute of Oncology Badalona, Hospital Germans Trias i Pujol, Badalona, Spain.
Zitieren
APA
Short, N. J., Ribera, J. M., Abou Dalle, I., Goulart, H., Ribera, J., Mohty, M., Torrent, A., & Bazarbachi, A. (2026). Evolving Paradigms in the Treatment of Philadelphia Chromosome–Positive ALL. American Society of Clinical Oncology Educational Book, 46(3). https://doi.org/10.1200/edbk-26-517464
Vancouver
Short NJ, Ribera JM, Abou Dalle I, Goulart H, Ribera J, Mohty M, et al. Evolving Paradigms in the Treatment of Philadelphia Chromosome–Positive ALL. American Society of Clinical Oncology Educational Book. 2026;46(3). doi:10.1200/edbk-26-517464
BibTeX
@article{Short2026,
author = {Short, Nicholas J and Ribera, Josep-Maria and Abou Dalle, Iman and Goulart, Hannah and Ribera, Jordi and Mohty, Mohamad and Torrent, Anna and Bazarbachi, Ali},
title = {Evolving Paradigms in the Treatment of Philadelphia Chromosome–Positive ALL},
journal = {American Society of Clinical Oncology Educational Book},
year = {2026},
volume = {46},
number = {3},
doi = {10.1200/edbk-26-517464}
}
EUVIMED